Written by Deep Kwatra
Published on Vol 5 Issue 1, 2025
Radiotherapy is a common treatment for cancer, though its effectiveness can be limited due to radiation resistance and damage to healthy tissues. Increasing the sensitivity of cancer cells to radiation while protecting normal cells is crucial for improving treatment outcomes. This study aimed to evaluate the radiosensitizing effects of tolmetin on human colon cancer cells (HT-29) during radiotherapy. HT-29 cells were divided into groups, with one receiving X-ray radiation and another receiving b
Read More
Written by Ahmed Samaouel Chehad
Published on Vol 5 Issue 1, 2025
Basal cell carcinoma (BCC) is a slow-growing, locally invasive form of skin cancer originating from basal cells, and it accounts for 75% of non-melanoma skin cancers. BCCs exhibit various clinical presentations, including nodular, superficial, morpheaform, and others. Most of these tumors appear in sun-exposed areas of the face and neck, while their occurrence in the nipple-areola complex is rare. When BCC arises in these areas, Paget’s disease of the breast must be excluded as a possibility. Fu
Read More
Written by Zhaobei Cai
Published on Vol 5 Issue 1, 2025
The survival rate for colorectal cancer has seen notable improvements thanks to advancements in early detection and treatment methods. As a result, the focus has increasingly shifted toward understanding the long-term health and well-being of survivors. This concern primarily revolves around three key areas: quality of life, psychological health, and financial burdens. In this article, we examine the quality of life of long-term colorectal cancer survivors, considering various treatment options
Read More
Written by Fatma Hussein Abdelwahab
Published on Vol 5 Issue 1, 2025
This research explores alternative cancer treatment options that minimize the severe side effects often associated with conventional therapies. Plasma medicine, a multidisciplinary field combining biology, clinical medicine, plasma physics, and chemistry, has emerged as a promising approach to cancer treatment. Stevia extracts, a natural sweetener derived from the Stevia plant, are known for their anti-cancer properties. The current study investigated the effects of gliding arc discharge (GAD) p
Read More
Written by Yeuan Ting Lee
Published on Vol 5 Issue 1, 2025
Cancer remains one of the most important health challenges of modern societies, prompting extensive global research efforts aimed at its control and eradication. Although numerous therapeutic strategies have been developed over time to combat cancer, the persistent issue of resistance exhibited by cancer cells—even against conventional chemotherapy—continues to hinder the success of treatment. Many of these therapeutic interventions fail to produce the desired outcomes due to the adaptability an
Read More
Written by İrem Sarıcanbaz
Published on Vol 5 Issue 1, 2025
Pancreatic cancer in older adults presents distinct challenges due to underlying comorbidities, functional status, and the lack of universally accepted treatment protocols. It is essential to assess the tolerability and efficacy of treatment in this demographic. The goal of our study was to evaluate the outcomes and tolerability of full-dose chemoradiation in pancreatic cancer patients aged 65 years and older. This retrospective study (2012-2019) involved 24 patients aged 65 years and older diag
Read More
Written by Z. Al-Balushi
Published on Vol 5 Issue 1, 2025
Ki-67 proliferation status measured by immunohistochemistry has long been discussed as both a prognostic and predictive indicator in breast carcinoma, yet its clinical robustness remains uncertain. In this analysis, Ki-67 was reassessed retrospectively by three independent pathologists using two scoring strategies—a whole-slide visual estimate and a focused quantitative count at the tumour edge—in a cohort of 411 early breast cancer patients followed for a median of 26.8 years. Agreement among o
Read More
Written by M. Flores
Published on Vol 5 Issue 1, 2025
The combination of nivolumab and ipilimumab has shown encouraging outcomes in treating metastatic non-small-cell lung cancer (NSCLC). However, its effectiveness in NSCLC patients who relapse after durvalumab consolidation following concurrent chemoradiotherapy (CCRT) remains unclear. This retrospective study analyzed clinical records of NSCLC patients treated with nivolumab plus ipilimumab between January 2021 and June 2022 after prior CCRT and durvalumab. A cohort of 30 individuals was included
Read More
Written by D. Toktogonov
Published on Vol 5 Issue 1, 2025
This study aimed to evaluate the preclinical activity and explore potential predictive biomarkers associated with polo-like kinase 1 (PLK1) inhibitors in experimental models of small cell lung cancer (SCLC). Cytotoxic responses to three PLK1-selective inhibitors—rigosertib, volasertib, and onvansertib—were examined across a panel of SCLC cell lines. Their therapeutic potential was further verified in subcutaneous xenografts from selected lines and in four patient-derived xenograft (PDX) systems
Read More
Written by I. Popovici
Published on Vol 5 Issue 1, 2025
Bariatric procedures have been linked to better prognoses in several cancers, including breast cancer (BC), though the biological drivers of this benefit remain unclear. We proposed that the rise in circulating bile acids observed after bariatric surgery could play a role in enhanced BC outcomes. Individuals whose tumors showed elevated levels of the bile acid-responsive receptor FXR had improved survival in specific aggressive BC phenotypes. FXR, a nuclear receptor activated primarily by endoge
Read More
Written by F. Al-Marzooqi
Published on Vol 5 Issue 1, 2025
This research aimed to examine the neoadjuvant chemotherapy (NACTx) pathway in breast cancer (BC) patients, highlighting major therapy-related adverse effects (trAEs), tumor response profiles, operative and histopathologic outcomes, and determining the predictors of cavity shaving and axillary lymph node dissection (ALND) after sentinel lymph node biopsy (SLNB). A retrospective single-institution analysis was performed on individuals who received NACTx for BC between 2015 and 2021. Records from
Read More
Written by E. Reyes
Published on Vol 5 Issue 1, 2025
Although considered early lesions, thin cutaneous melanomas still account for a notable portion of melanoma-related deaths, and their incidence continues to rise. We carried out a retrospective case-control analysis to determine which clinical-dermoscopic and histologic variables correlate with local or distant spread in melanomas measuring ≤0.8 mm. Records from 1 January 2000 through 22 June 2022 were reviewed from two specialized Italian dermatologic oncology centers. Sixteen individuals with
Read More
Written by J. Okello
Published on Vol 5 Issue 1, 2025
The interplay between metastasis-associated protein 1 and protein kinase B (MTA1/AKT) signaling has been implicated in driving prostate tumor expansion. Plant-derived polyphenols—especially stilbene compounds—have emerged as promising agents for interrupting MTA1-driven prostate malignancy. In this work, we utilized a prostate-specific transgenic mouse line featuring MTA1 overexpression combined with phosphatase and tensin homolog (Pten) deletion (R26MTA1; Ptenf/f), as well as PC3M prostate canc
Read More
Written by P. Barth
Published on Vol 5 Issue 1, 2025
Traditional circulating HPV DNA tests have had limited scope, so we examined the clinical usefulness of a newly developed next-generation sequencing (NGS)–based HPV ctDNA platform for people with locally advanced or metastatic squamous cell carcinoma of the anal canal (mSCCA). Plasma samples from patients with mSCCA were processed to extract ctDNA, which was analyzed using a 1.4 Mb hybrid-capture panel designed to cover the complete genomic sequences of all 193 known HPV types. A specialized ana
Read More
Written by Emily Moore
Published on Vol 5 Issue 1, 2025
Stomatitis represents a primary cause for discontinuing everolimus therapy among individuals diagnosed with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer. The DESIREE study explored a gradual dose-increase approach for everolimus (EVE esc) to mitigate mucositis and reduce premature discontinuations or dosage adjustments. This phase II, multicenter, randomized, double-blind, placebo-controlled investigation involved participants
Read More
Written by Jun M. Miller
Published on Vol 5 Issue 1, 2025
The combination of CDK4/6 inhibitors and endocrine therapy is now the standard first-line treatment for estrogen receptor-positive (ER+) metastatic breast cancer. Despite this, biomarkers predicting primary resistance to CDK4/6 inhibitors and the underlying mechanisms are still poorly understood. This study aimed to identify key molecular features and potential therapeutic targets associated with primary resistance to these inhibitors. An initial cohort of 36 patients treated with palbociclib pl
Read More
Written by Emily Fernandez
Published on Vol 5 Issue 1, 2025
The spread of tumors significantly worsens outcomes for individuals with gastric cancer. RNA-binding proteins (RBPs) play key roles in cancer spread, although their specific contributions to gastric cancer remain underexplored. In this work, we identified ESRP1, an epithelial-specific RBP, as a critical modulator of metastatic behavior in gastric cancer cells. Levels of ESRP1 show an inverse association with both distant and lymph node metastases in affected patients. Experiments confirmed that
Read More
Written by Yuki Fernandez
Published on Vol 5 Issue 1, 2025
SHR7390 represents an innovative and highly specific inhibitor targeting MEK1/2. The findings presented here stem from a pair of early-stage clinical studies aimed at assessing the safety, tolerability, and potential anticancer effects of SHR7390 used alone in cases of progressed solid malignancies, as well as in conjunction with camrelizumab for individuals with heavily pretreated advanced or metastatic colorectal cancer (CRC). Participants were administered SHR7390 either as a single agent or
Read More
Written by Yuki Hassan
Published on Vol 5 Issue 1, 2025
Studies in preclinical models have suggested that combining lurbinectedin with 5-fluorouracil enhances antitumor effects against solid tumors. This phase I clinical trial aimed to assess the safety, efficacy, and pharmacokinetics of combining capecitabine and lurbinectedin in patients with advanced solid tumors, with a particular focus on those with relapsed metastatic breast cancer (MBC). Patients in the trial were given capecitabine orally from day (D)1 to D14, alongside lurbinectedin administ
Read More
Our esteemed publisher is committed to advancing medical knowledge through rigorous research dissemination. We exclusively accept submissions related to the field of medicine.
Our journals provide a platform for clinicians, researchers, and scholars to share groundbreaking discoveries, clinical insights, and evidence-based practices. By maintaining this specialized focus, we ensure that their publications contribute significantly to the advancement of healthcare worldwide.
